Hiroki Kobayashi

Hiroki Kobayashi

Auto-generated profile, based on publicly available information

Hiroki Kobayashi

Department of Surgery, Nishijin Hospital

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in Blood
Verified
Journal Article
Closed access
PDF file
KMKosei Matsue
Kosei Matsue
YAYoshiaki Abe
Yoshiaki Abe
AKAkihiro Kitadate
Akihiro Kitadate
DMDaisuke Miura
Daisuke Miura
KNKentaro Narita
Kentaro Narita
KTKengo Takeuchi
Kengo Takeuchi

14 December 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
TUTomohiro Urata
Tomohiro Urata
YNYusuke Naoi
Yusuke Naoi
AJAixiang Jiang
Aixiang Jiang
MBMerrill Boyle
Merrill Boyle
KSKazutaka Sunami
Kazutaka Sunami
DEDaisuke Ennishi
Daisuke Ennishi
The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone (DZ) that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, which include the DZ signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a data set from the cohort of British Columbia Cancer (BCC) (n = 804). Through the 1050 patient samples on which DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to have germinal center B-cell–like (GCB) DLBCL, activated B-cell–like (ABC) DLBCL, and DZsig-positive (DZsigpos) DLBCL, respectively, with the highest prevalence of ABC-DLBCL, differing significantly from the BCC result (P < .001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with 2-year overall survival rates of 88%, 75%, and 66%, respectively (P < .0001), with patients with DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes after rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all, P < .05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.

8 April 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
HKHiroki Kobayashi
Hiroki Kobayashi
TTTakafumi Tsushima
Takafumi Tsushima
TTToshiki Terao
Toshiki Terao
YAYoshiaki Abe
Yoshiaki Abe
DMDaisuke Miura
Daisuke Miura
KMKosei Matsue
Kosei Matsue

18 June 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
AKAkihiro Kitadate
Akihiro Kitadate
KNKentaro Narita
Kentaro Narita
KFKouta Fukumoto
Kouta Fukumoto
TTToshiki Terao
Toshiki Terao
TTTakafumi Tsushima
Takafumi Tsushima
KMKosei Matsue
Kosei Matsue
Background Peripheral T‐cell lymphoma (PTCL) represents a heterogeneous and rare subgroup of aggressive lymphomas that generally demonstrate poor clinical outcomes with conventional treatment. Since the prognosis of PTCL is heterogeneous, more accurate risk assessment, and risk‐adapted treatment strategies are required. In this study, we examined whether interim positron emission tomography (iPET)‐computed tomography (PET/CT) results can be combined with baseline volume‐based metabolic assessments including total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) for risk stratification in PTCL. Methods The data of 63 patients with nodal PTCL, who had analyzable baseline PET/CT and iPET, were retrospectively reviewed. We calculated the baseline TMTV and TLG values. All iPET responses were analyzed using the Deauville 5‐point scale. Results On univariate analysis, a prognostic index for PTCL (PIT) higher than 2 (hazard ratio [HR], 2.03; P  = .026), high TMTV (>389 cm3; HR, 2.24; P  = .01), high TLG (>875; HR, 3.77; P  = .0005), and positive iPET (HR, 2.18; P  = .009) were significantly associated with poorer progression‐free survival (PFS). On multivariate analysis, only high TLG and positive iPET independently predicted both poorer overall survival (OS) and PFS. A model combining TLG and iPET showed that patients with low TLG and negative iPET had superior outcomes, with a 5‐year PFS and OS of 72% and 90%, respectively. Conversely, both 5‐year PFS and OS for those with high TLG and positive iPET were 0%. Conclusions In summary, TLG combined with iPET predicted survival in PTCL more accurately. This information may help in the development of risk‐adapted treatment strategies for PTCL.

3 January 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
HKHiroki Kobayashi
Hiroki Kobayashi
YAYoshiaki Abe
Yoshiaki Abe
DMDaisuke Miura
Daisuke Miura
KNKentaro Narita
Kentaro Narita
AKAkihiro Kitadate
Akihiro Kitadate
KMKosei Matsue
Kosei Matsue

4 January 2019 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
HKHiroki Kobayashi
Hiroki Kobayashi
YAYoshiaki Abe
Yoshiaki Abe
DMDaisuke Miura
Daisuke Miura
KNKentaro Narita
Kentaro Narita
AKAkihiro Kitadate
Akihiro Kitadate
KMKosei Matsue
Kosei Matsue
According to fluorescent in situ hybridization, t(11;14) is the most common cytogenetic abnormality in amyloid light-chain (AL) amyloidosis, but its prevalence in patients with AL amyloidosis and concurrent multiple myeloma (MM) remains unknown. We aimed to examine the prevalence of t(11;14) and the differences in clinical characteristics of patients with t(11;14) who had AL amyloidosis with or without concurrent MM. We retrospectively analyzed 40 patients with AL amyloidosis between January 2008 and January 2018 at our institution. The prevalence of t(11;14) was significantly higher in patients with AL amyloidosis alone compared with those with concurrent MM (56.5% vs. 17.6%; P = 0.022). This study suggests that AL amyloidosis patients with concurrent MM have a lower prevalence of t(11;14) than those without MM and that the presence of t(11;14) may be associated with poor prognosis, irrespective of the presence or absence of MM.